Intercell appoints Staph Leavenworth Bakali
pharmafile | October 27, 2010 | Appointment | Research and Development | Intercell, Staph Leavenworth Bakali, appointment, research and development
Austrian biotech company Intercell has appointed Staph Leavenworth Bakali as chief business officer.
He will have key responsibilities for the commercial aspects of the company, directly leading marketing and sales, corporate and business development, and alliance management.
Staph was previously a member of the company’s supervisory board, a role he relinquishes as part of his move to Intercell’s management board.
“Having been a member of Intercell’s supervisory board for almost five years, I have been impressed with the progress and capabilities of the company and its people in creating value through innovation, industrialisation and commercialisation”, Staph said. “I am delighted to join a very dynamic team and look forward to helping develop the business further.”
He brings 20 years of vaccine industry experience from his previous leadership positions, which have included serving as chief executive of US biotech Genocea Biosciences and chief operating officer for UK firm PowderJect.
Staph was also previously head of sales and marketing for Chiron’s global vaccine business and SmithKline Beecham’s Vaccine Business Unit in France.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






